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Monitored anesthesia care (MAC) is a safe, eﬀective, and appropriate form of anesthesia for many minor surgical procedures.
The proliferation of outpatient procedures has heightened interest in MAC sedation agents. Among the most commonly used
MAC sedation agents today are benzodiazepines, including midazolam, and propofol. Recently approved in the United States is
fospropofol, a prodrug of propofol which hydrolyzes in the body by alkaline phosphatase to liberate propofol. Propofol liberated
from fospropofol has unique pharmacological properties, but recently retracted pharmacokinetic (PK) and pharmacodynamic
(PD) evaluations make it diﬃcult to formulate clear conclusions with respect to fospropofol’s PK/PD properties. In safety and
eﬃcacy clinical studies, fospropofol demonstrated dose-dependent sedation with good rates of success at doses of 6.5mg/kg along
with good levels of patient and physician acceptance. Fospropofol has been associated with less pain at injection site than propofol.
The most commonly reported side eﬀects with fospropofol are paresthesia and pruritus. Fospropofol is a promising new sedation
agent that appears to be well suited for MAC sedation, but further studies are needed to better understand its PK/PD properties as
well its appropriate clinical role in outpatient procedures.
1.Introduction
One of the most profound changes in clinical practice in the
past two decades has been the migration of many procedures
from the inpatient to the outpatient setting. In 2006, about
two-thirds of all diagnostic and therapeutic procedures in
the United States were performed on an outpatient basis [1],
and procedures performed in freestanding ambulatory care
centers have increased 300% from 1996 to 2006 [2]. The
trend toward outpatient surgery has accelerated interest in
alternatives to general anesthesia (GA), including monitored
anesthesia care (MAC).
Propofol is a commonly used agent in MAC and other
clinical settings, but supplies of this agent are low, owing to
recalls and a possible decision by one manufacturer to no
longer make the drug [3]. Lean manufacturing techniques
can produce cost eﬀective products, but such a supply chain
can be particular vulnerable to disruptions such as voluntary
recalls and market shifts [4]. Thus, a drug of choice for
MAC sedation may be temporarily unavailable. Propofol has
also suﬀered from recent media attention on its potential
for misuse [5]. When a familiar agent is suddenly in short
supply, there may be potential safety risks to patients even if
an alternative agent(s) is available, in that clinicians may not
be familiar with the other agents, which may have a diﬀerent
mechanism of action, safety proﬁle, or other properties [6].
Fospropofol, a prodrug of propofol, might be considered
the “logical” alternative to propofol, but its potential role
in MAC sedation may have been aﬀected by a series of
pharmacokinetic studies [7–11] that had to be retracted
from the literature [12]. The current and potential role of
fospropofol in the MAC setting remains unclear.2 Anesthesiology Research and Practice
2.MonitoredAnesthesiaCare
MAC is not to be confused with moderate sedation,s o m e -
times called conscious sedation, deﬁned by the American
Society of Anesthesiologists (ASA) as sedation during which
the patient can be aroused by verbal commands or light
touch and in which a patent airway and stable cardiac and
respiratory functions can be maintained [13]. Moderate
sedation is not adequate for many procedures, including
some outpatient operations.
MAC has been deﬁned by the ASA as the speciﬁc service
of an anesthesiologist to a patient undergoing a diagnostic or
therapeutic procedure [14]. MAC is considered the standard
of care for patients undergoing a wide range of procedures,
such as minor surgeries [15], and is an appropriate choice
for delivery of anesthesia in many outpatient procedures
[16]. During MAC, the anesthesiologist or a member of the
anesthesia care team provides a number of speciﬁc services,
including, but not limited to, the following.
(i) Assessment and management of the patient’s actual
oranticipatedphysiologicalderangementsormedical
problems that may occur during a diagnostic or
therapeutic procedure.
(ii) Ability to convert to GA when necessary, due to the
likelihood that deep sedation may intentionally or
unintentionally transition to GA.
(iii) Ability to intervene in order to rescue the patient’s
airway from any sedation-induced compromise.
(iv) Readiness with acute clinical interventions and pos-
sible resuscitation in the event that medications
precipitate adverse physiologic responses.
(v) Monitoring of vital signs, maintenance of the
patient’s airway and continuous evaluation of vital
functions.
(vi) Diagnosis and treatment of clinical problems that
occur during the procedure.
(vii) Administration of sedatives, analgesics, hypnotics,
anesthetic agents, or other medications, as necessary,
to ensure patient safety and comfort.
(viii) Postprocedural responsibilities, including assuring a
full return to consciousness, pain relief, management
ofadversephysiologicalresponsesorsideeﬀectsfrom
medications administered during the procedure, as
well as diagnosis and treatment of coexisting medical
problems.
While morbidity and mortality were once the main
criteria by which to judge an anesthetic agent, today cost
eﬀectiveness and patient satisfaction must be taken into
account, although they can be diﬃcult to measure [17].
Patient dissatisfaction has been associated with measurable
v a r i a b l e ss u c ha sl o n g e rt i m ei nt h eo p e r a t i n gr o o m[ 18]
and postoperative symptoms in the ﬁrst 24 hours following
surgery [19], whereas improved patient satisfaction has been
associated with subjective variables such as patient-perceived
concern and courtesy exhibited by the clinical team [20, 21].
Cost eﬀectiveness is often assessed together with patient
satisfaction [22, 23], but their interrelationship poses its own
challenges [24].
Early cost eﬀectiveness studies of propofol found relative
acquisition costs of propofol expensive [25–27] but these
studies were done before a generic product was available.
Compared to sevoﬂurane, propofol (n = 104) exhibited
an improved recovery proﬁle, signiﬁcantly higher levels of
patient satisfaction, and overall lower costs [28]. However,
costeﬀectivenessstudiessometimesevaluateonlyacquisition
or procedural costs and do not factor in the expenses of
managing side eﬀects such as postoperative nausea and
vomiting (PONV) or postdischarge nausea and vomiting
(PDNV), which may increase the patient’s total cost of care
[29]. PONV/PDNV is one of the most common reasons for
outpatientstobeadmittedtothehospital,occurringinabout
1%ofpatients[30].TheratesofPONV/PDNVvarysubstan-
tially with several risk factors, including type of anesthesia,
type of procedure, and sex [31]. The incidence of PONV is
lower with propofol than sevoﬂurane (an inhalational agent
used in general anesthesia), but this may be an apples-to-
oranges comparison [32]. While PONV/PDNV following
ambulatory procedures is an important consideration, these
conditions have not been quantiﬁed in the literature for
fospropofol.
Current propofol labeling requires its administration by
an anesthesiologist [33] which may be argued to add to
its relative cost. While one economic model for the use of
propofolinGIproceduresfoundpropofolmorecosteﬀective
than meperidine and midazolam, even when accounting for
extrapersonnel[34],thecostsforananesthesiologyprovider
have been reported to add between $250 and $400 to the
cost of a colonoscopy [35]. For that and other reasons, the
FDA has been asked to approve propofol administration
by nonanesthesiologists in certain limited settings [35].
To bolster this point of view, a report in the literature
of global data from 646,080 cases found mortality rates
associated with endoscopist-directed propofol sedation were
similar to mortality rates of GA administered by anesthe-
siologists and superior to the published mortality rates for
endoscopist-administeredopioidsandbenzodiazepines[36].
There remains considerable controversy as to whether and
under what conditions propofol should ever be administered
bynonanesthesiologists[37–41].Acomputer-aidedpropofol
sedation system (Sedasys Computer-Assisted Personalized
Sedation System, Ethicon Endo-Surgery, Johnson & Johnson
Company, New Brunswick, NJ) has been designed to allow
gastroenterologists and nurses to administer propofol seda-
tion in speciﬁc outpatient procedures without beneﬁt of an
anesthesiologist by continuously monitoring and recording
such parameters as oxygen saturation, respiratory rate, heart
rate, blood pressure and end-tidal carbon dioxide [42]. This
system, which is approved in the European Union for certain
gastrointestinal (GI) procedures, was rejected by the FDA in
April 2010 [43].
Fospropofol disodium has recently been approved in
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undergoing diagnostic or therapeutic procedures (Lusedra,
Eisai, Research Triangle, NC) [44] and clinical trial data have
reported it to be eﬀective and generally well tolerated [45].
It is a water-soluble phosphate ester prodrug of propofol
[46], available in a single-dose vial for injection (35mg/ml),
requiring no infusion equipment. From a technological
aspect, fospropofol is easier to administer than propofol,
which may heighten the controversy as to whether or under
what circumstances fospropofol might be appropriately used
in MAC procedures by nonanesthesiologists. The safety
of fospropofol (Lusedra) for continuous sedation has not
been established and therefore its use is not recommended
[47]. Fospropofol was administered to 38 intubated and
mechanically ventilated patients in postoperative and inten-
sive care settings. An occurrence of nonsustained ventricular
tachycardia was observed as a serious adverse reaction in
one patient in the study. Another patient with acute myeloid
leukemia with renal and hepatic insuﬃciency experienced
a further increase in plasma format concentration from a
baseline of 66mcg/mL to a postdose level of 212mcg/mL
after a 12-hour infusion [47]. The clinical signiﬁcance of
these ﬁndings is unknown.
3. MAC Agents
The ideal sedation agent for MAC procedures would be
safe, eﬃcacious, cost eﬀective, convenient, with predictable
pharmacological properties and few side eﬀects. It should
also be well accepted by both patients and their physicians.
Among the most commonly used agents in MAC sedation
are benzodiazepines, in particular diazepam and midazolam,
and propofol. Benzodiazepines have been discussed in the
literature for use in outpatient colonoscopy procedures [48],
butmayhavesloworpotentiallyvariableonsetsofactionand
prolonged periods of eﬀect [16]. Of midazolam, diazepam,
and propofol, midazolam was associated with the longest
sedation and recovery times [49].
Propofol is an ultrashort-acting sedative hypnotic [50],
which releases aminobutyric acid in the brain [16]. It is
a phenolic derivative unrelated to other sedative/hypnotic
agents [51]. Propofol is available only in an oil-in-water
emulsion formulation, which readily crosses the blood-brain
barrier because of its highly lipophylic nature [52]. It has a
rapidonsetofsedation,thelevelofwhichincreasesinadose-
dependent fashion. Propofol is associated with injection-site
pain (incidence 32% to 67% for a single bolus) [53]a n d
carriesaslightbutpotentiallylethalriskofbacterialinfection
[54].
In a comparative study of outpatient colonoscopy
patients,thosewhoreceivedpropofolachievedasigniﬁcantly
greater mean level of sedation than similar patients with
midazolam/meperidine [55]. However, deeper sedation can
impair the patient’s cooperation during surgery (such as
turning) and may necessitate rescue to more moderate levels
of sedation.
Propofol’s narrow therapeutic index, lack of therapeutic
antagonist [56], and lipid formulation [57] limit its use in
some patient populations.
Fospropofol disodium (2,6-diisopropylphenoxymethyl
phosphate, disodium salt/C13H19O5PNa2)i san o v e lp r o -
drug, that is, a 2,6-dissoprophyl phenol molecule with a
methyl phosphate group substituted at the ﬁrst carbon
hydroxyl on the base benzene structure. Using a charged
phosphate group to replace a noncharged hydroxyl group
introduces electronegativity and allows fospropofol to dis-
solve readily in water. Such hydrophilic additions have a long
history of use in certain antibiotics and steroid drugs [58]. In
simple terms, fospropofol undergoes hydrolysis by alkaline
phosphatase in the endothelial cell surface, which causes
it to release the active metabolite propofol, formaldehyde
(which converts to formate) and phosphate [41, 59]. It
is thought that the liberated propofol increases activity of
gamma-aminobutyricacid(GABA)[60],thechiefinhibitory
neurotransmitters of the central nervous system (CNS),
binding to GABA receptors, and, in this way, potentiating
GABA-inhibitory synaptic currents [61]. See Figure 1.
An u m b e ro fa g e n t sc a nb eu s e df o rM A Cs e d a t i o n ,b u t
shortages of propofol have focused interest in fospropofol.
While the literature reports a great deal about midazolam,
benzodiazepam, and propofol, lessis known aboutthe newer
agent fospropofol.
4.Pharmacokinetics and
Pharmacodynamics of Fospropofol
The recent retraction [12] of six studies of the pharma-
cokinetic (PK) and pharmacodynamic (PD) properties of
fospropofol [7–11, 62] due to possible errors in propofol
assayshavecloudeddiscussionaboutthePK/PDoffospropo-
fol [63]. According to investigators, all six initial studies on
the pharmacokinetic and pharmacodynamic properties of
fospropofol and its tolerability had been published when an
analytical propofol assay inaccuracy was discovered [64]. All
six studies were phase I or phase II studies sponsored by
Guilford Pharma (Baltimore, MD). Guilford Pharma later
became MGI Pharma (Baltimore, MD). The studies were
conducted in two independent academic facilities in Europe
(Gent, Belgium and Erlangen, Germany). The sponsor
developed and validated a speciﬁc propofol assay and the
original publications were authored by both academic and
industry experts. When the error was detected, MGI Pharma
stated that it intended within 12 months to conduct further
studies, publish those results, and then using the new
results estimate the degree of error from the previously
published studies [63]. The matter was complicated when
the ownership of the drug was transferred in the middle of
2009 from MGI Pharma to Eisai (Woodcliﬀ Lake, NJ). The
original investigators were unable to conduct new studies
within the 12-month deadline and thus requested the studies
toberetractedbecausetheerrorandpossiblytheconclusions
reached in this studies were ﬂawed [64].
It is known that the PK characteristics of propofol
liberated from fospropofol diﬀer from the PK of propofol
emulsion administered intravenously [65]w i t hl o w e rp e a k
concentrations and more prolonged plasma concentrations
[66].4 Anesthesiology Research and Practice
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Figure 1: Formaldehyde converting to aldehyde dehydrogenase and then to formic acid (formate).
A randomized double-blind phase III study of 18 col-
onoscopy patients pretreated with fentanyl randomized to
6.5mg/kg or 2mg/kg fospropofol with midazolam as a
reference helped to develop the ﬁve-compartment PK model
of fospropofol [67]. This model shows fospropofol as a
two-compartment agent which liberates propofol, a three-
compartment model. See Figure 2.
The enzymatic process which liberates propofol from
fospropofol occurs within a 15 to 20-minute time window
[68], which creates a slower onset of action and, thus,
ad i ﬀerent sedation proﬁle than propofol emulsion. The
recommended maximum dose of fospropofol is 12.5mg/kg,
which should lead to loss of consciousness in about four
minutes [16]. The recommended eﬀective dose is 6.5mg/kg.
Fospropofol plasma concentrations were predictive of eﬀect-
site concentrations.
5. Efﬁcacy of Fospropofol in MAC Sedation
There are few published studies on clinical eﬃcacy of
fospropofol in MAC sedation. The authors reviewed four
clinical studies of fospropofol to evaluate its eﬃcacy, sum-
marized in Table 1.
Fospropofol resulted in signiﬁcant dose-dependent
increases in sedation success from 24% (2mg/kg), 35%
(5mg/kg),69%(6.5mg/kg)to96%(8mg/kg)(P<. 001)ina
randomized, double-blind clinical trial of 127 adult patients
undergoing sedation for a colonoscopy [69]. Patients were
pretreatedwith50μgoffentanylﬁveminutespriortotheini-
tial dose of sedative and then received either fospropofol (2,
5, 6.5 or 8mg/kg) or midazolam (0.02mg/kg). Supplemental
medication was permitted if needed to reach a modiﬁed
observer’s assessment of alertness/sedation (MOAA/S) of
≤4. The majority of fospropofol patients (all groups) had
mean MOAA/S scores ranging from 2 to 4 during the
colonoscopy. Midazolam, a frequently employed anesthetic
agent in colonoscopy, was used as a reference but not as a
direct comparator. Sedation success and patient satisfaction
were higher among the fospropofol groups than midazo-
lam patients. Patients in the 6.5mg/kg fospropofol group
reported higher satisfaction with fospropofol than the other
fospropofol dose groups. Patients reporting being satisﬁed
with fospropofol were, by percentage 72.0% for 2.0mg/kg;
84% for 5.0mg/kg; 92.3% for 6.5mg/kg; and 79.2% for
8.0mg/kg. Patient satisfaction in the midazolam group
was 69.2%. Physician satisfaction increased with dosage
of fospropofol (8.0% for 2.0mg/kg; 11.5% for 5.0mg/kg;
26.9% for 6.5mg/kg; and 50.0% for 8.0mg/kg; physician
satisfaction with midazolam was 11.5%). When patients
and physicians were asked if they would use this sedative
again, the greatest percentage in agreement occurred in the
fospropofol 6.5mg/kg group (96.2% for patients, 92.3% of
physicians). Physicians were signiﬁcantly more likely to say
they would use fospropofol again in the 6.5mg/kg group
than the 8.0mg/kg group (P<. 001).
A study by Cohen and colleagues compared 6.5mg/kg
of fospropofol to 2.0mg/kg in 314 patients undergoing
colonoscopy with midazolam 0.02mg/kg used as a reference
[70]. Patients were pretreated with fentanyl 50μc. Those
patients who received 6.5mg/kg of fospropofol had signiﬁ-
cantly greater sedation success (P<. 001), that is 87% for
6.5mg/kg versus 26% for 2.0mg/kg (midazolam was 69%)
and were signiﬁcantly less likely to remember being awake
during the procedure (P<. 001), having recall rates of 51%
for 6.5mg/kg versus 100% for 2.0mg/kg (midazolam 60%).
Memory retention was comparable for both fospropofol
doses (70% and 82%, resp.) and 41% for midazolam.
Physician satisfaction was signiﬁcantly higher for 6.5mg/kg
of fospropofol (P<. 001) compared to 2.0mg/kg.
Silvestri et al reported on the safety and eﬃcacy of
fospropofol in a phase III randomized, double-blind study
of ﬂexible bronchoscopy patients (n = 252) [71]. Following
pretreatment with fentanyl 50μg, patients were randomizedAnesthesiology Research and Practice 5
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Figure 2: The ﬁve-compartment model of fospropofol liberating propofol [67].
Table 1: Key clinical trials evaluating the use of fospropofol as an agent in MAC sedation.
Study n Procedure Pretreatment Dose (mg/kg)
of fospropofol
Other
agents? Conclusions
Cohen 2008
[69]
127 Colonoscopy 50μgf e n t a n y l 2 ,5 ,6 . 5 ,o r8 . 0
Midazolam
as reference
(0.02mg/kg)
Signiﬁcant dose-dependent increases in
sedation
Cohen et al.
2010 [70]
314 Colonoscopy 50μgf e n t a n y l 2 . 0o r6 . 5 Midazolam
(0.02mg/kg)
Signiﬁcantly greater sedation success,
greater memory retention, and higher
physician satisfaction at 6.5 than
2.0mg/kg of fospropofol
Silvestri et al.
2009 [71]
252 Flexible
bronchoscopy 50μgf e n t a n y l 2o r6 . 5 N o Signiﬁcantly higher sedation success at
6.5mg/kg (88.7% versus 27.5%, P<. 001)
Rex et al. 2007,
Safety and
Eﬃcacy [72]
314 Colonoscopy 50μgf e n t a n y l 2 . 0o r6 . 5 Midazolam
(0.02mg/kg)
Signiﬁcantly higher sedation success at
6.5mg/kg (87% versus 26%, P<. 001)
with signiﬁcantly greater depth of sedation
Rex et al. 2007,
Clear-headed
recovery [73]
314 Colonoscopy 50μgf e n t a n y l 2 . 0o r6 . 5 Midazolam
(0.02mg/kg)
Fospropofol patients (both doses) had
signiﬁcantly higher mean percentage of
retention postprocedure than midazolam
(P<. 001)
to receive fospropofol 2mg/kg or 6.5mg/kg. Supplemental
doses were given per protocol and the endpoint of the
study was sedation success as evaluated by three consecutive
MOAA/S scores of ≤4 plus procedure completion without
the need of alternative sedative or mechanical ventilation.
Sedation success rates were 88.7% (6.5mg/kg) and 27.5%
(2mg/kg) with signiﬁcantly more patients sedated success-
fully at the 6.5mg/kg dose (P<. 001). Patients given the
6.5mg/kg were signiﬁcantly more likely say they would use
that anesthesia again (P<. 001) and were signiﬁcantly more
likely to not recall the procedure (P<. 001). Patients dosed
with 6.5mg/kg of fospropofol were signiﬁcantly less likely
to require alternative sedation (P<. 001). The median
time to full alertness was 5.5min (6.5mg/kg) versus 3.0min
(2mg/kg).
The Silvestri study is of particular interest because 41%
of patients enrolled were geriatric (≥65 years old) and 43%
had an ASA Physical Classiﬁcation System status of 3 or 4,
that is, there was signiﬁcant comorbidity.
Rex and colleagues reported on a double-blind, ran-
domized, multicenter study of 314 patients undergoing
colonoscopy; in this study, patients were ﬁrst pretreated with
fentanyl 50μg and then received either 2.0 or 6.5mg/kg of
fospropofol or 0.02mg/kg of midazolam as a reference [72].
The 87% rate of sedation success in the 6.5mg/kg fospropo-
fol group was signiﬁcantly greater (P<. 001) than the
26% achieved with2.0mg/kg fospropofol(69% midazolam).
Furthermore, the mean time from ﬁrst dose to sedation was
signiﬁcantly briefer (P<. 0001) for 6.5mg/kg fospropofol
compared to 2.0mg/kg fospropofol (8.6 ± 5min versus
16.6 ± 5min, resp.). The time until patients were fully alert
was comparable in both fospropofol groups: 6.7 ± 7.5min
for 6.5mg/kg fospropofol compared to 8.9 ± 8.4min for
2.0mg/kg fospropofol (ﬁndings not statistically signiﬁcant).
The time until patients could be discharged was similar (and
not signiﬁcantly diﬀerent) in both groups: 8.7 ± 7.6min
for 6.5mg/kg fospropofol versus 8.9 ± 8.9minfor2.0mg/kg
fospropofol. There was a signiﬁcant diﬀerence in the depth6 Anesthesiology Research and Practice
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Figure 3: Learning and recall in fospropofol patients (2.0mg/kg
versus 6.5mg/kg) with midazolam as reference.
of sedation. Patients who received 6.5mg/kg fospropofol
had MOAA/S scores of 2 to 4 from the ﬁrst dose of study
medication to fully alert status 63.8% (±20.2) compared
to 47.2% (±20.9) among patients who received 2.0mg/kg
fospropofol. The depth of sedation was signiﬁcantly greater
for 6.5mg/kg than 2.0mg/kg fospropofol patients (P<
.001).
Rex and colleagues also evaluated sedation success and
clear-headed recovery in the same multicenter, double-blind
phase III clinical trial (n = 314) of patients undergoing
colonoscopy [73]. Cognitive testing at baseline (Hopkins
Verbal Learning Test-Revised) was performed to evaluate
recall and memory. Patients were randomized to receive fos-
propofol (2.0mg/kg), fospropofol (6.5mg/kg) or midazolam
(0.02mg/kg). At baseline, mean retention percentages for
verbal learning and recall were similar in all three groups,
but fospropofol groups (2mg/kg and 6.5mg/kg) had signif-
icantly higher mean percentage of retention postprocedure
than the midazolam patients (P<. 001), (see Figure 3). This
showed that patients receiving 6.5mg/kg fospropofol had
high rates of sedation success with better memory retention
than patients given midazolam.
These studies of fospropofol used midazolam rather
than propofol as comparator, but for clinical practice, it
may be more relevant to compare propofol to fospropofol.
Fospropofol is associated with less injection site pain than
propofol [11] and signiﬁcantly less respiratory depression
[41, 74]. The latter may make fospropofol particularly
useful in treating patients with comorbidities or at risk for
respiratory events.
6. Onset of Action
Predictable onset of action is crucial to a MAC sedation
agent, but both rapid and slow onset of action present dis-
tinct attributes that may be clinically useful. A MAC sedation
agent with a rapid onset of action allows for more immediate
andpossiblymorecomfortablesedation.Propofol,forexam-
ple,hasarapidonsetofaction,whichcanbeadvantageousin
the outpatient setting, where patient throughput and patient
satisfaction are particularly emphasized.
Fospropofol is generally considered to have a slow onset
of action of from four to 13 minutes compared to propofol,
which has a rapid onset of action of about 40 seconds [75].
This slower onset of action can be attributed to the fact
that fospropofol is a prodrug which must ﬁrst metabolize
in order to release propofol. This slower onset of action
may make it possible, in some instances, to oﬀer fewer
boluses of medication for a short operation, possibly making
fospropofol practical for use in an outpatient clinic per-
forming very brief diagnostic or therapeutic procedures. The
slow onset of action may require consideration in dosing,
recognizing that there is a “lag time” between infusion and
eﬀect.
7. Safety of Fospropofol in MAC Sedation
Paresthesia is one of the most commonly reported adverse
events with fospropofol sedation [46, 68, 69]. In the 2010
study by Cohen, paresthesia was reported to occur at a
rate of 68% in the 6.5mg/kg fospropofol group versus 60%
in the 2.0mg/kg group [70]. Pruritus occurred in 16% of
the 6.5mg/kg fospropofol group versus 26% of 2.0mg/kg
[70]. It has been observed that other medications containing
phosphate esters (such as dexamethasone) have provoked
similar side eﬀects [76]. Hypoxia was also observed with
fospropofol anesthesia, which investigators reported as mild
and comparable to rates observed with midazolam and
fentanyl. This hypoxia was resolvable with increased oxygen
ﬂow [71].
Fospropofol injections are associated with less pain than
propofol injections [11]a n da r ew e l lt o l e r a t e d[ 7].
The safety and tolerability of intravenous fospropofol
for MAC sedation in the outpatient setting was evaluated
in a recent study (n = 123) of patients undergoing minor
s u r g e r yw h ow e r eA S AP 1t oP 4[ 77]. All patients were
pretreatedwithfentanyl50μgandthenreceived6.5mg/kgIV
fospropofol and up to ﬁve supplemental doses (1.63mg/kg)
until an MOAA/S score of ≤4 was achieved to maintain ade-
quatesedation.Sedationdepth,needforsupplementaldoses,
use of alternative sedatives, and the nature of treatment-
emergentandsedative-relatedadverseeventsweremeasured.
The study found that 60% of patients could achieve adequate
sedation to initiate and complete the procedure with two
supplemental doses or fewer. About 5% required alternative
sedatives. Following the procedure, 61% of patients were
fully alert (MOAA/S = 5) two minutes after the procedure.
The most common treatment-emergent adverse events were
paresthesia(63%)andpruritus(28%).Adverseeventproﬁles
were similar in patients with hepatic disease (n = 20)
or severe renal dysfunction (n = 5). The investigators of
this study concluded that fospropofol had an acceptable
safety and tolerability proﬁle when used at an initial dose of
6.5mg/kg.Anesthesiology Research and Practice 7
8. Risks
In late 2009, the Deputy Administrator of the Drug
Enforcement Administration (DEA) of the United States
made fospropofol a schedule IV controlled substance [78].
Schedule IV drugs have a relatively low potential for abuse;
Schedule IV includes benzodiazepines and certain long-
acting barbiturates. While propofol has recently been in
world news because of its association with the death of
a prominent musician [79], propofol is not a controlled
substance, although there have been recommendations that
it be controlled by the Drug Enforcement Administration
[5]. There is currently no abuse data for fospropofol, but it
was determined that fospropofol could lead to physical or
psychological dependence, based on what is known about
propofol [78]. It has been speculated that fospropofol may
possess a greater degree of “likability” compared to propofol
by those who seek to misuse such drugs.
9. Conclusion
Theexpansionofoutpatientprocedureshasraisedinterestin
MAC sedation and appropriate MAC sedation agents. While
propofol is a frequently used agent in MAC sedation, it may
be subject to shortages that force focus on other agents. Its
prodrug fospropofol has been introduced to the market as
a potential MAC sedation agent, oﬀering a slower onset of
action and requiring no special infusion equipment. Limited
clinical experience and publications involving the use of
fospropofol coupled with having six fundamental PK/PD
fospropofol studies retracted have undermined the clinical
community’s ability to thoroughly assess this new drug and
its potential role in MAC sedation. Published safety and
eﬃcacy studies of colonoscopies and bronchoscopies have
clinical value, but are limited in that they report on the
use of fospropofol in relatively short procedures, rather than
longer procedures where repeated dosing might be required.
More studies using fospropofol in lengthier procedures are
needed. Furthermore, PK/PD studies of fospropofol are also
needed to clarify the pharmacological properties of the
agent. In terms of technical delivery, fospropofol may be
suitable to administration by nonanesthesiologists because
it requires no special infusion equipment, but whether
or not this is clinically appropriate remains controversial
and falls outside the scope of this paper. Fospropofol is
currently labeled to be administered by anesthesiologists
only.
When administered in an intravenous bolus, fospropofol
liberates propofol in the body, but this propofol has a
diﬀerent PK/PD proﬁle from the propofol of the propofol
emulsion. As such, fospropofol possesses a diﬀerent sedation
proﬁle than propofol. In particular, fospropofol has a slower
onset of action, which may confer advantages (less bolusing
in short procedures) or disadvantages (possibly reduced
patient comfort and more time spent in achieving adequate
sedation). The most commonly reported side eﬀects are
paresthesia and pruritus. Fospropofol overcomes the side
eﬀect of injection site pain common for propofol.
Fospropofol appears to be a promising new agent for
MAC sedation but further studies are warranted to better
evaluate its PK/PD properties and its appropriate role in the
outpatient setting. In light of current potential shortfalls of
propofol, such studies are urgently needed.
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